Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Adult Acute Lymphoblastic Leukemia Using a Post-remission Programme Whose Intensity Varies Depending on the Risk Class Defined on the Basis of Minimal Residual Disease.

NCT00358072 is registered in ClinicalTrials.gov with Northern Italy Leukemia Group as lead sponsor.

NCT NCT00358072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00358072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Adult Acute Lymphoblastic Leukemia Using a Post-remission Programme Whose Intensity Varies Depending on the Risk Class Defined on the Basis of Minimal Residual Disease.
Lead sponsor
Northern Italy Leukemia Group
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2000
Completion date
September 30, 2008
Enrollment
280 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia